GSA Capital Partners LLP Cuts Stake in Aadi Bioscience, Inc. (NASDAQ:AADI)

GSA Capital Partners LLP lessened its stake in shares of Aadi Bioscience, Inc. (NASDAQ:AADI) by 23.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,097 shares of the company’s stock after selling 6,392 shares during the period. GSA Capital Partners LLP owned about 0.09% of Aadi Bioscience worth $43,000 as of its most recent SEC filing.

Separately, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Aadi Bioscience during the 2nd quarter worth approximately $37,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on AADI shares. Piper Sandler lowered Aadi Bioscience from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $5.00 to $1.75 in a report on Tuesday, August 27th. Jefferies Financial Group cut Aadi Bioscience from a “buy” rating to a “hold” rating and lowered their price objective for the company from $11.00 to $1.50 in a research note on Wednesday, August 21st. TD Cowen downgraded shares of Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Piper Sandler Companies cut shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 price target on the stock. in a research note on Tuesday, August 27th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Aadi Bioscience in a research note on Wednesday, August 21st. Five analysts have rated the stock with a hold rating, According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $1.67.

Aadi Bioscience Stock Down 3.5 %

Shares of AADI opened at $2.22 on Tuesday. Aadi Bioscience, Inc. has a twelve month low of $1.21 and a twelve month high of $5.70. The stock has a market cap of $54.72 million, a PE ratio of -0.97 and a beta of 0.71. The business’s 50-day moving average price is $2.04 and its 200-day moving average price is $1.78.

Aadi Bioscience (NASDAQ:AADI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.46) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.46). The business had revenue of $7.21 million for the quarter, compared to analyst estimates of $6.55 million. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. During the same quarter in the prior year, the firm posted ($0.60) EPS. Analysts expect that Aadi Bioscience, Inc. will post -1.98 earnings per share for the current fiscal year.

Insider Activity at Aadi Bioscience

In other Aadi Bioscience news, Chairman Neil Desai sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $1.71, for a total value of $68,400.00. Following the sale, the chairman now owns 1,171,543 shares of the company’s stock, valued at $2,003,338.53. This trade represents a 3.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 37.30% of the stock is owned by corporate insiders.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.